Alan Akira, MD
Psychiatry · Chicago, ILNPI 1710470257
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 63.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $2,927 and has fallen 81.6% since, to $537 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $172.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$559
- Alkermes, Inc.$285
- Johnson & Johnson$272
- E.r. Squibb & Sons, L.L.C.$144
- Neurocrine Biosciences, Inc.$124
- plus $324 from 3 others
What the payments were for
- Consulting fees$1,23026%
- Speaking & faculty fees$1,23026%
- Food & beverage$2,18447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $2,936 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $559 |
| Alkermes, Inc. | 4 | $285 |
| Johnson & Johnson | 3 | $272 |
| E.r. Squibb & Sons, L.L.C. | 1 | $144 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Indivior Inc. | 1 | $119 |
| AbbVie | 1 | $111 |
| Tris Pharma Inc | 2 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,644 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 11 | $11,905 |
| Clozapine | 186 | $10,833 |
| Clozapine OdtClozapine | 45 | $6,593 |
| Risperidone OdtRisperidone | 26 | $3,902 |
| Paliperidone ErPaliperidone | 22 | $1,626 |
| Haloperidol | 41 | $961 |
| Lithium Carbonate ErLithium Carbonate | 34 | $680 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 56 | $608 |
| Haloperidol Decanoate | 11 | $538 |
| Valproic AcidValproic Acid (As Sodium Salt) | 16 | $430 |
| Perphenazine | 30 | $400 |
| Lurasidone Hcl | 14 | $388 |
| Trazodone Hcl | 60 | $324 |
| Quetiapine Fumarate | 49 | $313 |
| Benztropine Mesylate | 37 | $309 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Chicago
- Mitchell GlaserChicago$752K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Jeffrey RadoChicago$208K
- K Ranga KrishnanChicago$92K
- Richard BaerChicago$44K
- Adam GoldenbergChicago$23K
- Olusola AjiloreChicago$21K
- Emil CoccaroChicago$20K
- Guarava AgarwalChicago$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.